Currently viewing the tag: "USPTO"

Seneste nyt fra USPTO.

By On 17. October 2012 · Leave a Comment · In BioPorto

I starten af August 2012 skrev  Stengaard et indlæg vedrørende traume patentet’s behandling hos de amerikanske patentmyndigheder USPTO.  The recent development in Triage/Trauma NGAL-patent.

Der er nu kommet nyt materiale i den sag, i form af svar fra  Bioportos patentsagfører i USPTO, Kristina Bieker-Brady.

Applicant Arguments/Remarks Made in […]

Continue Reading →

The BioP US patent family, who’s next…

By On 29. June 2012 · Leave a Comment · In BioPorto

Bioporto has filed for more US patents,  all related to measurement of NGAL. One thing strikes you when you look at the various applications.

Take a look for yourself – if at first you don´t see the common denominator  scroll down

 

 

Exclusion patent.

 

The ratio patent:

 

The CutOff patent:

 

scroll […]

Continue Reading →

The Important First US NGAL-patent

By On 27. June 2012 · 1 Comment · In BioPorto

Today BioPorto was granted their first US patent (the ratio patent) . This is truly a milestone… Hip-Hip-Hooray… The Patent is measuring the ratio between NGAL levels in urine and plasma.

Why is this important – you might ask…

A: it is the FIRST US patent – its significance can not be overrated

B: It is […]

Continue Reading →
Set your Twitter account name in your settings to use the TwitterBar Section.